Most alloantibodies developed in congenital hemophilia A patients undergoing FVIII replacement therapy, which are classified as type I inhibitors of first-order kinetics, inactivate FVIII at a rate linearly correlated with their concentration and are able to completely inhibit FVIII activity at high concentrations. Here, F8 is linked to hemophilia A.